Abstract
To investigate the correlation between retinol binding protein 4 (RBP4), lipoprotein associated phospholipase A2 (LP-PLA2), we studied the clinical phenotype of coronary heart disease (CHD) and the severity of coronary artery disease. Our studies showed that the changes of retinol binding protein 4, LP-PLA2 serum concentration has a relation with the severity of coronary artery disease progression, but no clear relationship with the degree of coronary artery lesion and count. Furthermore, LP-PLA2 concentration increases with the increase of the severity of coronary artery disease and disease occurrences.
Highlights
Coronary heart disease is one of the common diseases in cardiology
Numbers of animal and human studies have shown that when its level rising, which is closely related to the changes in insulin resistance, diabetes, central obesity, primary hypertension, lipid metabolism, such as changes in lipid profile and so on [1, 4], is a cardiovascular disease risk factors, may be directly or indirectly through a variety of ways involved in the occurrence and development of coronary heart disease, but the specific mechanism of action has not yet elucidated
The results showed that LP-PLA2 concentration in coronary heart disease was significantly higher than that in control group (P
Summary
Coronary heart disease is one of the common diseases in cardiology. Many risk factors and chronic inflammatory reaction can lead to the formation of coronary heart disease. One of the common risk factors is dyslipidemia. Lipid deposition in the vascular wall, causing atherosclerosis and plaque formation lumen narrowing, results in loss of oxygen and oxygen consumption out of balance. Plaque rupture can lead to a series of coronary events, in which the inflammatory reaction in the arteriosclerosis process plays a certain role in triggering. Early detection of chronic inflammatory reactions offers a potential strategy for the cardiovascular disease prevention
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
